Stockreport

Compelling Data on Mechanism of Action for GlycoMimetics’ Late-stage Clinical Candidate Uproleselan Published in Nature Communications

GlycoMimetics, Inc.  (GLYC) 
Last glycomimetics, inc. earnings: 5/1 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.glycomimetics.com/investor-relations
PDF Research shows that uproleselan is a potent antagonist of E-selectin, can break chemoresistance ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) to [Read more]